PTEN and cancer: Although, none of these newly derived cell lines displayed prostate cancer characteristics, future approaches, e.g., targeted mutation of SPOP, FOXA1 or PTEN, which have been discussed as prostate cancer driver alterations, offer a tool for research on prostate cancer initiation and early cancer progression.